Business Description
Nabriva Therapeutics PLC
ISIN : IE000OZRGNV6
Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 0.02 | |||||
14-Day RSI | 0.52 | |||||
3-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -44.32 | |||||
OCF Margin % | -43.93 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-Revenue | 0.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NBRVF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nabriva Therapeutics PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29.387 | ||
| EPS (TTM) ($) | -18.43 | ||
| Beta | 88.863 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 115.8 | ||
| 14-Day RSI | 0.52 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.0001 - 0.0002 | ||
| Shares Outstanding (Mil) | 3.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nabriva Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nabriva Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 26 days | ||
| Annual report for 2025 | 2026-07-20 | In 2 days | ||
| General meeting for 2025 | 2026-07-20 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-07-17 | 0.00 (+0.00%) | ||
| 0.04:1 Stock Split | 2022-09-16 | 6.68 (-7.61%) | ||
| 0.1:1 Stock Split | 2020-12-03 | 98.45 (+6.43%) | ||
| 10:1 Stock Split | 2017-06-26 | 2,755.00 (-4.17%) |
Show
Entries
Nabriva Therapeutics PLC Frequently Asked Questions
What is Nabriva Therapeutics PLC(NBRVF)'s stock price today?
The current price of NBRVF is $0.00. The 52 week high of NBRVF is $0.00 and 52 week low is $0.00.
When is next earnings date of Nabriva Therapeutics PLC(NBRVF)?
The next earnings date of Nabriva Therapeutics PLC(NBRVF) is 2026-07-17 Est..
Does Nabriva Therapeutics PLC(NBRVF) pay dividends? If so, how much?
Nabriva Therapeutics PLC(NBRVF) does not pay dividend.
Guru Commentaries on OTCPK:NBRVF
No articles.
Press Release
Articles on Nabriva Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers